Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention With XIENCE.

NCT03218787 is registered in ClinicalTrials.gov with Abbott Medical Devices as lead sponsor.

NCT NCT03218787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03218787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention With XIENCE.
Lead sponsor
Abbott Medical Devices
Phase
Not applicable
Overall status
Completed
Start date
July 19, 2017
Completion date
September 4, 2020
Enrollment
2,047 (actual)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery lesions